canadian compounding pharmacy semaglutide Health Canada's market authorisation for our generic Injection makes us the first company to receive this authorisation in Canada. This milestone reflects our deep focus on complex generics and peptide based Semaglutide for weight loss |

As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide is not currently approved in the UK and remains available only within authorised clinical trials

However, federal law gives states the option whether to cover drugs used for weight loss

Resuming GLP-1 after surgery depends on adequate oral intake, normal bowel function, stable recovery, and medical team approval, with possible dose re-titration after prolonged cessation

The February 2026 test measured 99.90%

NPY, neuropeptide Y

Figures reported by Research and Markets support this, projecting the potential market size for GLP-1 receptor agonists to reach US$173.62 billion by 2030